Reviews/Novel Antibiotics/Dalbavancin osteomyelitis efficacy
Lipoglycopeptides · NOVEL-AB-LIPOGLY-03 · v2
Borderline: within 4 points of the Uncertain/Doubtful boundary, so a re-grade could land either side.
The claim is that dalbavancin works for osteomyelitis and deep bone infections. The corpus contains exactly one study that actually tests this: a retrospective look-back [7] at 136 patients with diabetic foot osteomyelitis, reporting a cure rate of 80.9%. There was no comparison group, most patients had already failed other antibiotics, and nearly three-quarters also had surgery, so it is impossible to credit the cure to dalbavancin alone. The other strong trials of dalbavancin in the corpus [2][3][6] treated skin or bloodstream infection, not bone, and the broader 'deep-seated' infections such as spine or prosthetic-joint are not tested at all. The panel judged that one confounded, single-phenotype study cannot support such a broad efficacy claim, which is why it landed where it did.
Only [7] directly addresses dalbavancin in bone infection, reporting a cure rate of 80.9% (95% CI: 73.5-86.6%) in diabetic foot osteomyelitis, with dalbavancin used as second-line therapy in 92% of cases. The randomised trials of dalbavancin [2][3] established noninferiority for acute bacterial skin and skin-structure infection, and [6] showed benefit in catheter-related bloodstream infection, but these concern different infection compartments. [4] is a bone-and-joint infection trial but tests oral versus intravenous route with no dalbavancin arm. No randomised controlled trial of dalbavancin in osteomyelitis or deep-seated bone infection exists anywhere in this corpus. The contested point: The division is between a single positive observational signal [7] and the absence of any controlled or broader bone-infection evidence to support it. In [7], surgical interventions were required in 72% of cases and minor amputations in 40%, so whether the 80.9% cure reflects the drug or the surgical management cannot be resolved from the corpus.
All 20 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Novel Antibiotics, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
Only one admissible primary study ([7]) addresses dalbavancin in bone infection, and it is retrospective and uncontrolled with no comparator arm; no RCT exists in the corpus for this indication.
[7] is confined to diabetic foot osteomyelitis; the claim's 'deep-seated bone infections' (vertebral osteomyelitis, prosthetic-joint, native deep bone) has zero primary efficacy evidence in the corpus — the claim overreaches its support.
Where it remains uncertain. The cure rate in [7] has no comparator arm and 72% of patients also underwent surgery, while the strongest dalbavancin trials [2][3][6] treated skin or bloodstream infection, not bone.
Aleatory
A cure rate of 80.9% from 136 patients in [7] carries sampling variability (95% CI: 73.5-86.6%) and comes from one patient series.
Epistemic
The corpus contains no RCT of dalbavancin in osteomyelitis; the dalbavancin trials present [2][3][6] are skin or bloodstream infection.
Inferential
In [7], 72% had surgery and 40% minor amputations, so cure cannot be isolated to dalbavancin.
The load-bearing papers from a corpus of 20, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Sole direct primary evidence of dalbavancin efficacy in osteomyelitis (diabetic foot), uncontrolled
“Dalbavancin is effective and safe for treating diabetic foot osteomyelitis, including in complex patients with resistant microorganisms.”
Panel auditInternal validity: low · scope of inference: Patients with diabetic foot osteomyelitis, mostly as second-line therapy alongside surgery.Key limitations: no control arm · retrospective · confounded by surgery and prior therapy
1 of 20 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
One confounded, phenotype-restricted observational study with no controlled or broader bone-infection evidence places the broad claim at the Uncertain floor.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No controlled trial in bone infection. The only direct study [7] has no comparator, so the 80.9% cure cannot be benchmarked against standard therapy or natural course under surgery. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A randomised controlled trial of dalbavancin versus standard-of-care antibiotics for osteomyelitis with a predefined cure endpoint.
Open question: Does dalbavancin cure osteomyelitis better than or as well as standard-of-care antibiotics? Why it is still open: The only bone-infection study [7] is uncontrolled with no comparator arm, and no RCT exists in the corpus.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19